Cargando…
Conventional CARs versus modular CARs
The clinical application of immune effector cells genetically modified to express chimeric antigen receptors (CARs) has shown impressive results including complete remissions of certain malignant hematological diseases. However, their application can also cause severe side effects such as cytokine r...
Autores principales: | Feldmann, Anja, Arndt, Claudia, Koristka, Stefanie, Berndt, Nicole, Bergmann, Ralf, Bachmann, Michael P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805801/ https://www.ncbi.nlm.nih.gov/pubmed/31542798 http://dx.doi.org/10.1007/s00262-019-02399-5 |
Ejemplares similares
-
T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression
por: Kegler, Alexandra, et al.
Publicado: (2019) -
Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019) -
From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
por: Albert, Susann, et al.
Publicado: (2018) -
Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
por: Arndt, Claudia, et al.
Publicado: (2020) -
Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers
por: Loureiro, Liliana R., et al.
Publicado: (2020)